Status:
TERMINATED
Dipeptidyl Peptidase-4 Inhibition on Glucagon-like Peptide-1 (GLP-1)
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Glucose Homeostasis
Eligibility:
All Genders
21-75 years
Phase:
PHASE2
Brief Summary
This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1...
Detailed Description
The purpose of the present proposal is to 1) examine the role of dipeptidyl peptidase (DPP-4) inhibition on insulin release during a hyperglycemic clamp while GLP-1 is being infused and, 2) further el...
Eligibility Criteria
Inclusion
- Hct level of at least 34% for women and 36% for men
- Women of non-bearing potential and women of childbearing potential using adequate contraception
- Serum creatine level of less than 1.7 mg/dl
- Four groups:
- Age 21-45 (BMI between 18.50-24.99) \& (BMI between 30-35)
- Age greater than 65 years (BMI between 18.50-24.99) \& (BMI between 30-35)
Exclusion
- Pregnant and/or lactating females
- Women of childbearing potential not willing to use adequate contraception
- Hct below inclusion criteria
- Serum creatine level greater than 1.8 mg/dl
- Age less than 21 and age between 46-64
- Diabetes mellitus
- BMI less than 18 and BMI greater than 35
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00947011
Start Date
March 1 2009
End Date
March 1 2010
Last Update
July 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States, 21224